Traditional cardiovascular risk factors do not entirely account for the increased risk of atherosclerosis, the major cause of death, in systemic lupus erythematosus (SLE). In this project we want to identify new pathogenic pathways of atherosclerosis in SLE patients, by assessing the association between newly identified potential risk factors and a refined measure of subclinical atherosclerosis, soft (noncalcified) coronary plaque. Similarly over 50% of SLE patients develop lupus nephritis, including 75% of African-American SLE patients. Renal biopsy is the gold standard to determine renal activity, but is expensive, invasive, and has real risk to the patient. We hypothesize that urinary markers of renal activity will have clinical utility in human lupus nephritis, as they have in renal transplant patients and murine models of SLE. In addition we want to develop and study three new approaches to assess hypercoagulability risk (endogenous thrombogenic potential, complement activation, and platelet microparticles) to determine if these markers can predict future thrombotic events or associated with antiphospholipid antibodies.

Public Health Relevance

Although the survival of SLE patients has greatly improved, permanent organ damage continues to occur in the general public. This project addresses three challenges: hardening of the arteries, blood clots, and lupus kidney disease in collaboration with other rheumatologists and radiologists.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Research Project (R01)
Project #
Application #
Study Section
Cardiovascular and Sleep Epidemiology (CASE)
Program Officer
Witter, James
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Hardt, Uta; Larsson, Anders; Gunnarsson, Iva et al. (2018) Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. Arthritis Res Ther 20:36
Pejchinovski, M; Siwy, J; Mullen, W et al. (2018) Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus. Lupus 27:6-16
Little, Jayne; Parker, Ben; Lunt, Mark et al. (2018) Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology (Oxford) 57:677-687
Iftikhar, Mustafa; Kaur, Ramandeep; Nefalar, April et al. (2018) MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study. Retina :
Merrill, Joan T; Petri, Michelle A; Buyon, Jill et al. (2018) Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Sci Med 5:e000263
Eudy, Amanda M; Siega-Riz, Anna Maria; Engel, Stephanie M et al. (2018) Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis 77:855-860
Davidson, Julie E; Fu, Qinggong; Ji, Beulah et al. (2018) Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis. J Rheumatol 45:671-677
Bernatsky, Sasha; Ramsey-Goldman, Rosalind; Petri, Michelle et al. (2018) Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. J Rheumatol 45:393-396
Costedoat-Chalumeau, Nathalie; Houssiau, Frédéric; Izmirly, Peter et al. (2018) A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clin Pharmacol Ther 103:1074-1082
Giannakou, Ioanna; Chatzidionysiou, Katerina; Magder, Laurence S et al. (2018) Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. Lupus Sci Med 5:e000287

Showing the most recent 10 out of 220 publications